Peter Irving
0000-0003-0972-8148
King's College London
10 papers found
Refreshing results…
Conserved γδ T cell selection by BTNL proteins limits progression of human inflammatory bowel disease
Thromboprophylaxis Use in Paediatric Inflammatory Bowel Disease: An International RAND Appropriateness Panel
Systematic Literature Review and Meta-analysis: Real-World Mucosal Healing in Vedolizumab-Treated Patients with Crohn’s Disease
Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic
Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel
British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic
The Clinical and Cost-Effectiveness of 4 Enzyme-Linked Immunosorbent Assay Kits for Monitoring Infliximab in Crohn Disease Patients: Protocol for a Validation Study
Missing publications? Search for publications with a matching author name.